Med 22. in 23. marcem 2018 je v Bukarešti potekal četrti sestanek partnerjev projekta AD-GAMING-oblikovanje programa usposabljanja za uporabo “resnih iger” za izboljšanje kakovosti življenja oseb z Alzheimerjevo boleznijo. Vsi partnerji projekta (Grčija, Španija, Velika Britanija, Romunija in Slovenija) so poročali o dosedanjem delu. V Sloveniji smo do marca 2018 skupno izvedli 25 delavnic »resnih
V četrtek, 29.03.2018, je Spominčica v Domu ob Savinji Celje s strokovnimi delavci izvedla delavnico za uporabo »resnih iger« pri delu z osebami z demenco. V uvodnem delu sta predstavnici Spominčice opisali temeljne značilnosti in namen projekta AD-GAMING, v katerem sodeluje 5 evropskih držav: Španija, Grčija, Velika Britanija, Romunija in Slovenija. Namen projekta je pripraviti
Dr. Rafael Simó is the Director of Diabetes and Metabolism Research Unit at Vall d’Hebron Research Institute (VHIR), Head of the Diabetes Section of the Endocrinology Department at Vall d’Hebron University Hospital, and Professor of Medicine & Endocrinology at the Autonomous University of Barcelona. Prof. Simó is the Vice-President of the European Association of Diabetes
Anders Wimo, MD, PhD, adjunct professor, Center for Alzheimer Research at Karolinska Institutet, Stockholm, Sweden and family physician, the county council of Gävleborg, Sweden. He is the coordinator of the steering committees of the population project Swedish National study on Aging and Care (SNAC) and a member of the Swedish dementia quality assurance register (SveDem).
Dr. Mercè Boada is a neurologist, co-founder and medical director of Fundació ACE. She has published 150 scientific papers. As a PI she has been conducting over 110 clinical trials since 1996. She is focused on the treatment of Alzheimer’s disease and related dementias. She has developed her professional career in Catalonia and Spain and
MOPEAD Citizen Science activity is designed to reach a big number of citizens through an online marketing campaign, thus contributing to a global paradigm shift towards early diagnosis. For the purpose of MOPEAD Citizen Science, online advertisement campaign adapted to each MOPEAD country will be developed. Through these online campaigns, as many citizens as possible will be attracted to the Citizen Science web page where a series of validated questions will be asked to them.
Interview with Annette Dumas, ASDM Consulting, EU Affairs Director How does MOPEAD fit into wider EU actions around ageing, and dementia in particular? Dementia, a condition that mainly affects elderly people, has been recognised as a public health priority worldwide. The number of people living with dementia in Europe (around 7 million), combined with an
Interview with Bengt Winblad, Professor of Geriatric Medicine at the Karolinska Institutet, Head of Division of Neurogeriatrics and Director of the Swedish Brain Power research network. What are the main challenges for health care practitioners (HCPs) when dealing with AD? The ageing of the population in Europe is leading to an increase in the number
Interview with Laura Campo, MOPEAD project leader, International Corporate Affairs, Alzheimer’s disease at Eli Lilly and Company. Why is EARLY diagnosis of Alzheimer’s disease (AD) important? The current academic understanding of Alzheimer’s disease (AD) pathogenesis and management emphasizes the need for an early detection. In clinical practice, diagnosis is still occurring late in the disease
Interview with Merce Boada, MOPEAD project leader, Founder and Medical Director of Fundació ACE, Institut Català de Neurociències Aplicades. What are the issues addressed by MOPEAD, how will MOPEAD help to solve these issues? The difficulty of diagnosing Alzheimer’s disease (AD) in the very early stages lies in the belief of the general population, and